Eurartesim

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

piperaquine tetraphosphate, Artenimol

Available from:

Alfasigma S.p.A.

ATC code:

P01BF05

INN (International Name):

piperaquine tetraphosphate, artenimol

Therapeutic group:

Antiprotozoals

Therapeutic area:

Malarija

Therapeutic indications:

Eurartesim je indicirano za zdravljenje nezapleteno Plasmodium falciparum malarije odrasle, otroke in dojenčke 6 mesecev in več in tehta 5 kg ali več. Upoštevati je treba uradne smernice za ustrezno uporabo proti malariji agenti.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2011-10-27

Patient Information leaflet

                                38
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Alfasigma S.p.A.
Via Ragazzi del ’99, n. 5
40133 Bologna
Italija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/11/716/005 3 filmsko obložene tablete
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Eurartesim
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC: {številka} [koda zdravila]
SN: {številka} [serijska številka]
NN: {številka} [nacionalna številka povračila stroškov za zdravilo
ali druga nacionalna številka za
identifikacijo zdravila]>
39
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
Eurartesim 160 mg/20 mg tablete
piperakin tetrafosfat/artenimol
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Alfasigma S.p.A
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
_ _
EXP
4.
ŠTEVILKA SERIJE
_ _
Lot
5.
DRUGI PODATKI
40
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA
1.
IME ZDRAVILA
Eurartesim 320 mg/40 mg filmsko obložene tablete
piperakin tetrafosfat/artenimol
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 320 mg piperakin tetrafosfata (v
obliki tetrahidrata) in 40 mg
artenimola.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložene tablete – 3 tablete
filmsko obložene tablete – 6 tablet
filmsko obložene tablete – 9 tablet
filmsko obložene tablete – 12 tablet
filmsko obložene tablete – 270 tablet
filmsko obložene tablete – 300 tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
peroralna uporaba
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA PO
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
_ _
_ _
_ _
_ _
_ _
_ _
2
1.
IME ZDRAVILA
_ _
Eurartesim 160 mg/20 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena filmsko obložena tableta vsebuje 160 mg piperakin tetrafosfata (v
obliki tetrahidrata; PKP) in
20 mg artenimola.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Bele podolgovate bikonveksne filmsko obložene tablete (dimenzije 11,5
x 5,5 mm/debelina 4,4 mm) z
razdelilno zarezo in oznako na eni strani s črkama „S“ in
„T“.
Tableta se lahko deli na enake odmerke.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Eurartesim je indicirano za zdravljenje nezapletene malarije
_Plasmodium falciparum _
pri
odraslih, mladostnikih, otrocih in dojenčkih, starih 6 mesecev in
več in težkih 5 kg ali več.
_ _
Upoštevati je treba uradna navodila glede ustrezne uporabe
antimalarikov, vključno z informacijami o
razširjenosti odpornosti na artenimol/piperakin na geografskem
območju, kjer je prišlo do okužbe
(glejte poglavje 4.4).
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Zdravilo Eurartesim je treba dajati tri zaporedne dni ob isti uri,
torej skupno tri odmerke.
Odmerjanje naj temelji na telesni masi, kot je prikazano v spodnji
tabeli:
TELESNA
MASA (KG)
DNEVNI ODMEREK (MG)
JAKOST TABLETE IN ŠTEVILO TABLET NA ODMEREK
PKP
ARTENIMOL
5 do <7
80
10
½ x 160 mg / 20 mg tablete
7 do <13
160
20
1 x 160 mg / 20 mg tableta
13 do <24
320
40
1 x 320 mg / 40 mg tableta
24 do <36
640
80
2 x 320 mg / 40 mg tableti
36 do <75
960
120
3 x 320 mg / 40 mg tablete
>75*
1.280
160
4 x 320 mg / 40 mg tablete
* Glejte poglavje 5.1.
3
Če bolnik v 30 minutah po uporabi zdravila Eurartesim bruha, je treba
odmerek dati ponovno; če
bolnik bruha v 30–60 minutah, je treba ponovno dati polovico
odmerka. Zdravila Eurartesim ne
poskušajte dajati ponovno več kot enkrat. Če bolnik drugi odmerek
izbruha, je treba uvesti zdravljenje
z alternativnim antimalarikom.
Če bolnik izpusti odm
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-08-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-08-2023
Public Assessment Report Public Assessment Report Bulgarian 26-09-2016
Patient Information leaflet Patient Information leaflet Spanish 30-08-2023
Public Assessment Report Public Assessment Report Spanish 26-09-2016
Patient Information leaflet Patient Information leaflet Czech 30-08-2023
Public Assessment Report Public Assessment Report Czech 26-09-2016
Patient Information leaflet Patient Information leaflet Danish 30-08-2023
Public Assessment Report Public Assessment Report Danish 26-09-2016
Patient Information leaflet Patient Information leaflet German 30-08-2023
Public Assessment Report Public Assessment Report German 26-09-2016
Patient Information leaflet Patient Information leaflet Estonian 30-08-2023
Public Assessment Report Public Assessment Report Estonian 26-09-2016
Patient Information leaflet Patient Information leaflet Greek 30-08-2023
Public Assessment Report Public Assessment Report Greek 26-09-2016
Patient Information leaflet Patient Information leaflet English 30-08-2023
Public Assessment Report Public Assessment Report English 26-09-2016
Patient Information leaflet Patient Information leaflet French 30-08-2023
Public Assessment Report Public Assessment Report French 26-09-2016
Patient Information leaflet Patient Information leaflet Italian 30-08-2023
Public Assessment Report Public Assessment Report Italian 26-09-2016
Patient Information leaflet Patient Information leaflet Latvian 30-08-2023
Public Assessment Report Public Assessment Report Latvian 26-09-2016
Patient Information leaflet Patient Information leaflet Lithuanian 30-08-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-08-2023
Public Assessment Report Public Assessment Report Lithuanian 26-09-2016
Patient Information leaflet Patient Information leaflet Hungarian 30-08-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-08-2023
Public Assessment Report Public Assessment Report Hungarian 26-09-2016
Patient Information leaflet Patient Information leaflet Maltese 30-08-2023
Public Assessment Report Public Assessment Report Maltese 26-09-2016
Patient Information leaflet Patient Information leaflet Dutch 30-08-2023
Public Assessment Report Public Assessment Report Dutch 26-09-2016
Patient Information leaflet Patient Information leaflet Polish 30-08-2023
Public Assessment Report Public Assessment Report Polish 26-09-2016
Patient Information leaflet Patient Information leaflet Portuguese 30-08-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-08-2023
Public Assessment Report Public Assessment Report Portuguese 26-09-2016
Patient Information leaflet Patient Information leaflet Romanian 30-08-2023
Public Assessment Report Public Assessment Report Romanian 26-09-2016
Patient Information leaflet Patient Information leaflet Slovak 30-08-2023
Public Assessment Report Public Assessment Report Slovak 26-09-2016
Patient Information leaflet Patient Information leaflet Finnish 30-08-2023
Public Assessment Report Public Assessment Report Finnish 26-09-2016
Patient Information leaflet Patient Information leaflet Swedish 30-08-2023
Public Assessment Report Public Assessment Report Swedish 26-09-2016
Patient Information leaflet Patient Information leaflet Norwegian 30-08-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-08-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-08-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-08-2023
Patient Information leaflet Patient Information leaflet Croatian 30-08-2023
Public Assessment Report Public Assessment Report Croatian 26-09-2016

Search alerts related to this product

View documents history